Eligibility criteria matter when a trial is cited as evidence for an entire condition. This study selected women with fibromyalgia and low IGF-1 rather than an unrestricted fibromyalgia population. Primary trial
Study findings
Fifty women entered a randomized, double-blind, placebo-controlled nine-month study. The reported endpoint groups contained 22 growth-hormone and 23 placebo recipients. Symptom and tender-point scores favored growth hormone at nine months, with much of the response appearing after several months. Carpal tunnel symptoms were more frequent with growth hormone, and symptoms worsened after discontinuation. Primary report
Our appraisal: selection, timing, and harms belong together
Low IGF-1 was part of entry into the study. It should not be assumed that the same effect applies to patients with different endocrine findings. Nor does a response to an intervention establish that one hormonal defect explains every symptom of the underlying condition.
Enrollment and endpoint analysis counts differ. Full review should explain the missing participants, their reasons for leaving, and how their outcomes were handled. A complete-case result may differ from an analysis that preserves everyone initially assigned.
The delayed response also limits an “immediate benefit” interpretation. Repeated assessments can reveal a trajectory, but the chosen endpoint and any multiplicity handling should remain clear. A selected favorable visit should not be substituted for the full pattern.
Carpal tunnel symptoms are an important tolerability observation, not an incidental footnote. They should be considered alongside benefit estimates, discontinuation, and the possibility that noticeable effects could influence blinding.
This historical trial supplies a signal in a selected subgroup. It does not establish a routine fibromyalgia treatment recommendation, a diagnostic shortcut for growth-hormone deficiency, or durable benefit after stopping treatment. Full participant flow, outcome definitions, and adverse-event reporting need review before broader clinical claims are made.
Frequently asked questions
Were participants selected for low IGF-1?
Yes.
Did the reported endpoint groups total all 50 enrolled women?
No; participant flow needs reconciliation.
Was the response predominantly immediate?
No; improvement was delayed in many participants.
Were carpal tunnel symptoms more frequent?
Yes.
Did symptoms worsen after discontinuation?
The authors reported that pattern.
Does this represent every patient with fibromyalgia?
No.
Does treatment response prove a single cause of the condition?
No.